Lupin expects 25 per cent growth in next three years
The Company expects its global sales to grow at a healthy pace of 25 per cent for the next three years.
New Delhi, April 21, 2013: Lupin expects its sales to continue growing at a pace of 25 per cent globally for the next three years. The company is confident about the growth trend as the contributions are equally strong from all the markets where it is present. The company has not limited itself to India.
Lupin already has 11 approvals in the oral contraceptive space in the US and the company recently received a favourable ruling form a US court paving the way for it to introduce a generic version of Bayer AG's Yaz tablets in American market.
The company expects its India operations to grow around 18-20 per cent.